Slides
Page 1
Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s DiseaseOctober 28, 2025
Page 2
Forward Looking StatementThis presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “design,” “enable” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “project,” “should,” “target,” “towards,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this presentation include those regarding Vor Bio's plans for development and commercialization of telitacicept; the potential therapeutic benefits of telitacicept in various indications including generalized myasthenia gravis (gMG) and primary Sjögren's disease; the potential of telitacicept to be a best-in-disease and a disease modification in gMG and Sjogren’s; the potential benefits of the dual BAFF/APRIL mechanism; the expected safety profile of telitacicept; the market opportunities for telitacicept; the addressable patient populations in the indications Vor Bio intends to treat; and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation, completion of, and availability and timing of results from, preclinical studies and clinical trials; whether preclinical data or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the uncertainty of regulatory approvals to conduct trials or to market products; Vor Bio's reliance on third parties over which it may not always have full control; and the availability of funding sufficient for Vor Bio's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this Presentation speak only as of the date of this Presentation, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.Certain information contained in this Presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and Vor Bio's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this Presentation, the Company has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. In addition, there can be no guarantee as to the accuracy or reliability of any assumptions or limitations that may be included in such third-party information. While the Company believes its own internal research is reliable, such research has not been verified by any independent source. All brand names or trademarks appearing in this Presentation are the property of their respective owners. 2
Page 3
AgendaOpening Remarks & Data Highlights 3 Jean-Paul Kress, M.D., Chairman & Chief Executive OfficerSjögren’s Disease – A Major Unmet NeedRonald van Vollenhoven, M.D., Ph.D.,Professor of Rheumatology at Amsterdam University Medical Center 1. 2. Primary Sjögren’s Disease China Phase 3 ResultsQing Zuraw, M.D., M.P.H., M.B.A., Chief Development Officer3. Competitive Landscape & Commercial OpportunityDallan Murray, Chief Commercial Officer4. Closing Remarks5. Jean-Paul Kress, M.D., Chairman & Chief Executive Officer
Page 4
AANEM | Redefining Durability in gMG with Telitacicept gMG, generalized myasthenia gravis; *MGFA Scientific Session/AANEM 2025 Abstract; †Not placebo adjusted4 48-week OLE results oral presentation on October 29, 2025 at 10:50AM PTMG-ADL Change From Baseline† -5.74 Week 24 -7.5 Week 48* -8.66 Week 24 -9.8 Week 48*QMG Change From Baseline†Deep, sustained duration of response over time underscores BAFF/APRIL inhibitionSignificant MG-ADL and QMG score reduction experienced by placebo crossover patientsConsistent safety and tolerability over one year of therapyOpportunity to become the first disease modifying therapy in gMG
Page 5
A True Signal, No Noise•No DMARDs, no steroidsClinically Meaningful, Statistically Clear•Robust, dose-dependent improvements across physician- and patient-assessed outcomesDepth and Durability Across Domains•Improvement of systemic activity, symptoms, and functionConsistent Safety Profile•No new safety signals. No opportunistic infection reported. ACR | Potential to Redefine Treatment in pSD 5 Telitacicept showed statistically significant and clinically meaningful improvement in pSD -4.4 Telitacicept 160mg -3.0 Telitacicept 80mg -0.6 Placebo Group Change in ESSDAI score from baseline at Week 24 -1.9 Telitacicept 160mg -1.3 Telitacicept 80mg -0.4Placebo Group Change in ESSPRI score from baseline at Week 24 P <0.0001 P <0.0001 PSD, primary Sjogren's disease; The analysis of change from baseline in ESSDAI and ESSPRI score over Weeks 0-24 was based on the estimate population (EP). The MMRM method was used and missing data were not imputed. The analysis of change from baseline in ESSDAI and ESSPRI score over Weeks 0-48 was based on the estimate population (EP). The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results. P <0.0001 P <0.0001
Page 6
Early, Broad Symptom Improvements Observed with Telitacicept 6 Nearly 90% of patients report improvement as physicians confirm disease control in 3 out of 4 patients Placebo*: Participants randomized to the placebo group. ⁜The analysis of change from baseline in ESSDAI and ESSPRI score over Weeks 0-24 was based on the estimate population (EP). The MMRM method was used and missing data were not imputed. ⁑The analysis of change from baseline in ESSDAI and ESSPRI score over Weeks 0-48 was based on the estimate population (EP). The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results.RemeGen-sponsored trial 73.0% 16.5%0%10 %20 %30 %40 %50 %60 %70 %80 %90 %10 0% 4812162024283236404448WEEK 16 0mg80 mgPlacebo PROPORTION OF PARTICIPANTS WITH ≥3-POINT REDUCTION FROM BASELINE IN ESSDAI SCORE OVER TIME⁜⁑ 49.1% ##Ϯ#Ϯ#ǂ############## (*P<0.05,ϮP<0.01,ǂP<0.001,#P<0.0001) 33.3% 0%10 %20 %30 %40 %50 %60 %70 %80 %90 %10 0% 4812162024283236404448WEEK 16 0mg80 mgPlacebo PROPORTION OF PARTICIPANTS WITH ≥1-POINT OR ≥15% REDUCTION FROM BASELINE IN ESSPRI SCORE OVER TIME⁜⁑ 89.1%75.4% #####################*#
Page 7
Potential Disease Modification Through Upstream and Downstream Control BAFF, B-cell activating factor; BLyS, B Lymphocyte Stimulator; APRIL, a proliferation inducing ligand7 Dual BAFF/APRIL blockade is designed to stop B cell survival and plasma cell antibody production Regulated by APRILRegulated by BAFF / BLyS Antibodies TelitaciceptTACI-Fc fusion protein: dual inhibition of BAFF/APRILBlocking BAFF inhibits abnormal development and maturation of B cellsTelitacicept inhibits immature B cells from developing into mature cells, with the goal of slowing down disease progression Blocking APRIL inhibits abnormal production of antibodies by plasma cellsTelitacicept inhibits mature B cells from differentiating into plasma cells, minimizing antibodies abnormally produced by plasma cells and contributing to a reasonable control of disease activitiesBAFFAPRIL doi.org/10.3390/cancers12041045
Page 8
Harnessing Native TACI Biology for Optimal Binding 1. DOI 10.1074/jbc.M411714200; 2. DOI 10.3389/fimmu.2018.02125; 3. WO2002094852A2; 4. Internal Telitaicept IP8 Preserving receptor integrity enhances binding strength and supports a favorable safety profile Natural Design AdvantageMimics full native TACI structure (N-terminus + CRD1/2) Native Structure Enables Optimal BindingN-Terminus + CRD1/2 preservation targets more natural ligand engagement with BAFF and APRIL1,2 Safety DifferentiationWild-type mimicry designed for cleaner tolerability vs truncated designs N-Terminus CRD1 CRD2 Stalk TM Intracellular Domain N-Terminus CRD1 CRD2Stalk FC Telitacicept4WT TACI3
Page 9
Telitacicept: Redefining What Success Looks Like In Autoimmune Disease 2021 - Systemic Lupus Erythematosus (SLE)†2024 - Rheumatoid Arthritis (RA)2025 – Generalized Myasthenia Gravis (gMG) †Conditional Approval, Full Approval in 2023; *Accelerated Approval in China9 Clinically meaningful results in every late-stage program with consistent efficacy and safety1 2 3 4 5 6 3 Commercial Approvals in ChinaPrimary Sjogren’s Disease (pSD, Filed 2025)IgA Nephropathy (IgAN, Filed 2025)* 2 BLA Submissions in ChinaUnique Dual BAFF/APRIL Inhibition Drives Superior Clinical Benefit in SLE, pSD, gMG in China Best-In-Disease Leadership Proven real-world impact at commercial scale 10s of Thousands of Patients Treated in ChinaNo burdensome vaccinationNo B-cell depletion-related SAEsMild to moderate AEs Favorable Safety ProfileSafety profile confirmed in ~1,800 patients across 6+ indications in ChinaAE rates comparable to placebo Consistent Tolerability
Page 10
Sjögren’sdisease–a major unmetneedRonald van Vollenhoven Department of Rheumatology and Clinical Immunology
Page 11
Disclosures•Research Support (institutional grants): AstraZeneca, BMS, Cabaletta, Novartis, Remegen•Support for Educational programs (institutional grants): Alfasigma, AstraZeneca, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, UCB•Consultancy and/or speaker: AbbVie, AstraZeneca, Biogen, BMS, Cabaletta, Galapagos, GSK, Janssen, Kyowakirin, Pfizer, RemeGen, Sanofi, UCB, Vor Bio
Page 12
Sjögren’s Disease Xavier Mariette, M.D., Ph.D., and Lindsey A. Criswell, M.D., M.P.H., D.Sc.; PublishedMarch7, 2018; N EnglJ Med 2018;378:931-939; DOI: 10.1056/NEJMcp1702514; VOL. 378 NO. 10; 2018 A multi-organ systemic autoimmune disease
Page 13
Sjögren’s Disease (Sjögren’s syndrome) •Incidence 3-11/100,000•Prevalence 0.5%•Female-male 9:1•2 peaks: 20-30 and menopause•Autoantibodies:§SSA = anti-Ro§SSB = anti-La•ACR-EULAR classification criteria
Page 14
Pathophysiology: chroniclymphocyticinflammatorion https://en.wikipedia.org/wiki/Sj%C3%B6gren%27s_disease
Page 15
Diagnosis ≠ classification
Page 17
Sjögren’s Disease (Sjögren’s syndrome) •Primary•Secondary à Overlap§RA, lupus, SSc etc. •Glandular and extraglandular•“Autoimmune exocrinopathy”•“Autoimmune epithelitis”
Page 18
https://creakyjoints.org/living-with-arthritis/symptoms/sjogrens-syndrome-symptoms/
Page 19
Multiple domainsare affected
Page 21
ESSDAI: EULAR Sjogren’ssyndromediseaseactivityindex
Page 22
Overlap among the systemic autoimmune diseases
Page 23
SLE: systemiclupus erythematosus(erythematodes); “lupus”
Page 24
Leading causes and consequences of organ damage in SLE QoL = quality of life. Adapted from Doria A, et al. Autoimmun Rev 2014;13:770–777.
Page 25
Telitacicept: an effective new therapy for SLE Van Vollenhoven et al, NEJM, 2025
Page 26
Conclusions•Sjogren’s disease:§an important chronic autoimmune disease§major burden on patients’ quality of life§limited treatment options •New treatments are emerging for Sjogren based on pathophysiology, including those that target B-cells•For lupus, a closely related disease, recent data support the efficacy and safety of the Blys/APRIL antagonist telitacicept
Page 27
Primary Sjögren’s Disease China Phase 3 ResultsQing Zuraw, M.D., M.P.H., M.B.A., Chief Development Officer 27
Page 28
28 Phase 3 Trial in Primary Sjögren's Disease Completed in ChinaPotential best-in-disease profile in China; randomized, double-blind, placebo-controlled study *Estimated. ESSDAI, EULAR Sjögren’s syndrome disease activity index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; MFI, multidimensional fatigue inventory; MFI-20, multidimensional fatigue inventory; PGA, physician’s global assessment; PaGA, patient’s global assessment; SF-36, 36-item short-form; pSD, primary Sjögren’s disease; QW, per week. 380* Adults With pSD Primary Endpoint•Change from baseline in ESSDAI at 24 weeksSecondary Endpoints•Change from baseline in ESSDAI at 12 weeks•Changes from baseline in ESSPRI, PGA, PaGA,SF-36 and MFI-20 at12 and 24 weeks Double-Blind Treatment Period(24 Weeks) R 1:1:1 Telitacicept(80mg QW)Telitacicept(160mg QW) Double-Blind Treatment Period(24 Weeks) Telitacicept(80mg QW)Telitacicept(160mg QW) Placebo RemeGen-sponsored trial PlaceboR 1:1
Page 29
Patient Disposition 29 Strong study execution across 79 sites in China *Participants randomized to the placebo group; †Participants who did not switch treatment throughout the trial; Teli, telitaciceptRemeGen-sponsored trial Screening (n=480) Randomized (n=381) Received Treatment in Stage A (n=380)Placebo* (n=127) Telitacicept 160mg (n=127)Telitacicept 80mg (n=126)Treatment Discontinuation (n=21) Study Discontinuation (n=8)Treatment Discontinuation (n=15) Study Discontinuation (n=10)Treatment Discontinuation (n=22) Study Discontinuation (n=8) Entered Stage B (n=118)Entered Stage B (n=119)Placebo†(n=24) Teli 160mg (n=48)Teli 80mg (n=47) Treatment Completed (n=17)Study Completed (n=20) Treatment Completed (n=46)Study Completed (n=46)Treatment Completed (n=42)Study Completed (n=43)Treatment Completed (n=106)Study Completed (n=110)Treatment Completed (n=112)Study Completed (n=114) Entered Stage B (n=119) Treatment Discontinuation (n=7) Study Discontinuation (n=4)Treatment Discontinuation (n=5) Study Discontinuation (n=4)Treatment Discontinuation (n=2) Study Discontinuation (n=2)
Page 30
Baseline Characteristics 30 Well-balanced, representative patient population across treatment arms SD: standard deviation; BMI: body mass index; Mon, months; ESSDAI, EULAR Sjögren’s syndrome disease activity index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; MFI-20, multidimensional fatigue inventory; Telitacicept 160mgTelitacicept 80mgPlaceboTotal(n=127)(n=127)(n=127)(n=381)Age (yr), Mean (SD)45.9 (12.29)44.6 (12.06)47.3 (12.75)46.0 (12.39)Body Weight (kg), Mean (SD)55.89 (9.04)56.88 (8.71)56.99 (11.08)56.58 (9.65)BMI (kg/m2), Mean (SD)22.03 (3.16)22.31 (3.19)22.24 (3.58)22.19 (3.31)Sex, n (%), Female124 (97.6)124 (97.6)123 (96.9)371 (97.4)pSD Duration (mon), Mean (SD)21.388 (36.32)25.831 (46.90)19.930 (39.57)22.383 (41.14)ESSDAI Score, Mean (SD)10.0 (3.77)9.8 (3.52)10.2 (4.17)10.0 (3.82)ESSDAI ≥10 points, n (%)63 (49.6)61 (48.0)63 (49.6)187 (49.1)ESSPRI Score, Mean (SD)5.07 (1.60)4.91 (1.72)5.08 (1.76)5.02 (1.69)MFI-20 Total Score, Mean (SD)56.8 (12.08)56.8 (12.50)58.1 (13.07)57.2 (12.54)Baseline Hydroxychloroquine Use, n (%)87 (68.5)97 (76.4)99 (78.0)283 (74.3)IgG (g/L), Mean (SD)21.459 (7.43)22.429 (7.95)22.297 (7.21)22.062 (7.53)IgA (g/L), Mean (SD)3.435 (1.63)3.637 (1.86)3.154 (1.68)3.409 (1.73)IgM (g/L), Mean (SD)1.458 (0.64)1.372 (0.92)1.274 (0.70)1.368 (0.77)CD19+ B Cell (cells/μL), Mean (SD)209.412 (129.10)183.993 (109.52)266.902 (726.52)220.102 (430.96) RemeGen-sponsored trial
Page 31
Deep, Consistent ESSDAI Reduction Through 48 Weeks 31 7x greater improvement means fewer active symptoms and broader systemic relief for patients Placebo*: Participants randomized to the placebo group. ⁜The analysis of change from baseline in ESSDAI score over Weeks 0-24 was based on the estimate population (EP). The MMRM method was used and missing data were not imputed. ⁑The analysis of change from baseline in ESSDAI score over Weeks 0-48 was based on the estimate population (EP). The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results. -4.4-5.5 -4.5 -3.5 -2.5 -1.5 -0.5 04812162024 CHANGE FROM BASELINE (POINT) IN ESSDAI SCORE WEEK 16 0mg80 mgPlacebo CHANGE FROM BASELINE (POINT) IN ESSDAI SCORE OVER WEEKS 0-24⁜ -0.6 -3.0 *#####Ϯǂ### -3.2 -0.4 -4.6-5.5 -4.5 -3.5 -2.5 -1.5 -0.5 04812162024283236404448 CHANGE FROM BASELINE (POINT) IN ESSDAI SCORE WEEK 16 0mg80 mgPlacebo CHANGE FROM BASELINE (POINT) IN ESSDAI SCORE OVER WEEKS 0-48⁑ ##Ϯ#ǂ################## RemeGen-sponsored trial (*P<0.05,ϮP<0.01,ǂP<0.001,#P<0.0001)
Page 32
Deep, Consistent ClinESSDAI Reduction Through 48 Weeks ESSDAI and ClinESSDAI remain nearly identical at week 48 -4.6 vs -4.5ClinESSDAI excludes biological domain (IgG, complement), representing a more sensitive measure of pure clinical disease activity 32 Sustained improvement in clinical benefit beyond serologic change ClinESSDAI, clinical ESSDAI; Placebo*: Participants randomized to the placebo group. ⁜The analysis of change from baseline in ClinESSDAI score over Weeks 0-24 was based on the estimate population (EP). The MMRM method was used and missing data were not imputed. ⁑The analysis of change from baseline in ClinESSDAI score over Weeks 0-48 was based on the estimate population (EP). The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results.RemeGen-sponsored trial -3.2 -0.6 -5.5 -4.5 -3.5 -2.5 -1.5 -0.5 04812162024283236404448 CHANGE FROM BASELINE (POINT) IN CLINESSDAI SCORE WEEK 16 0mg80 mgPlacebo CHANGE FROM BASELINE (POINT) IN CLINESSDAI SCORE OVER WEEKS 0-48⁜⁑ -4.5
Page 33
More Than Half of Patients Achieve Low Disease Activity 33 Nearly 5x more patients on 160mg vs placebo achieved this threshold Low Disease Activity (ESSDAI <5) Represents Minimal Systemic Involvement 55% vs 12%Consistent improvement sustained through 48 weeks, indicating durable immune stabilization Placebo*: Participants randomized to the placebo group. ⁜The analysis of change from baseline in ESSDAI score over Weeks 0-24 was based on the estimate population (EP). The MMRM method was used and missing data were not imputed. ⁑The analysis of change from baseline in ESSDAI score over Weeks 0-48 was based on the estimate population (EP). The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results. (*P<0.05,ϮP<0.01,ǂP<0.001,#P<0.0001) 55.0% 12.2%0%10 %20 %30 %40 %50 %60 %70 %80 %90 %10 0% 4812162024283236404448WEEK 16 0mg80 mgPlacebo PROPORTION OF PARTICIPANTS WITH ESSDAI SCORE <5 POINTS OVER TIME⁜⁑ 32.7% ǂ#*#*#Ϯ#ǂ#Ϯ#Ϯ#ǂ#ǂ#ǂ#ǂ*
Page 34
Sustained Improvement in ESSPRI Through 48 Weeks 34 Reduction in patient-reported fatigue, pain, and dryness by ~2.6 points at one year Placebo*: Participants randomized to the placebo group. ⁜The analysis of change from baseline in ESSPRI score over Weeks 0-24 was based on the estimate population (EP). The MMRM method was used and missing data were not imputed. ⁑The analysis of change from baseline in ESSPRI score over Weeks 0-48 was based on the estimate population (EP). The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results.RemeGen-sponsored trial (*P<0.05,ϮP<0.01,ǂP<0.001,#P<0.0001) -1.88 -3 -2.5 -2 -1.5 -1 -0.5 0 04812162024 CHANGE FROM BASELINE (POINT) IN ESSPRI SCORE WEEK 16 0mg80 mgPlacebo CHANGE FROM BASELINE (POINT) IN ESSPRI SCORE OVER WEEKS 0-24⁜ -0.36 -1.31 *#####Ϯ#### -1.74 -0.41 -2.56-3 -2.5 -2 -1.5 -1 -0.5 0 04812162024283236404448 CHANGE FROM BASELINE (POINT) IN ESSPRI SCORE WEEK 16 0mg80 mgPlacebo CHANGE FROM BASELINE (POINT) IN ESSPRI SCORE OVER WEEKS 0-48⁑ ##Ϯ#ǂ##################
Page 35
Telitacicept Produced Clinically Meaningful Improvement in Fatigue 35 12-point improvement over 48 weeks to a critical daily symptom for patients Placebo*: Participants randomized to the placebo group. ⁜The analysis of change from baseline in MFI-20 score over Weeks 0-24 was based on the estimate population (EP). The MMRM method was used and missing data were not imputed. ⁑The analysis of change from baseline in MFI-20 score over Weeks 0-48 was based on the estimate population (EP). The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results. -9.6-10 -8 -6 -4 -2 0 2 04812162024 CHANGE FROM BASELINE (POINT) IN MFI-20 TOTAL SCORE WEEK 16 0mg80 mgPlacebo CHANGE FROM BASELINE (POINT) IN MFI-20 TOTAL SCORE OVER WEEKS 0-24⁜ 0.3 -3.4 ǂ####*ϮϮ -5.1 -12.3-13-12-11-10-9-8-7-6-5-4-3-2-1012 04812162024283236404448 CHANGE FROM BASELINE (POINT) IN MFI-20 TOTAL SCORE WEEK 16 0mg80 mgPlacebo CHANGE FROM BASELINE (POINT) IN MFI-20 TOTAL SCORE OVER WEEKS 0-48⁑ 0.0##Ϯ#ǂ################## RemeGen-sponsored trial (*P<0.05,ϮP<0.01,ǂP<0.001,#P<0.0001)
Page 36
BAFF/APRIL MOA Associated With Improvement Across All ESSPRI Domains -2.2 -1.8 -1-1.4 -1.1 -1-0.6 -0.2 0 -2.5-2-1.5-1-0.50 DrynessFatigueJoint/Muscle Pain CHANGE FROM BASELINE IN ESSPRI SCORE BY DOMAIN AT 24 WEEKS 160mg80mgPlacebo MOA, mechanism of action36 Meaningful improvement across dryness, fatigue, and pain – symptoms that define daily patient life
Page 37
STAR: Exploratory Endpoint Demonstrates Multi-Domain Improvement 37 Nearly 3 in 4 patients achieved ≥5 point response Placebo*: Participants randomized to the placebo group. A STAR responder was defined as a participant with a total STAR score of ≥5 points. Participants with missing scores in any domain (except those with a total STAR score of ≥5 points despite missing scores in some domains) were imputed as “non-responders”. The responder proportion analysis for Weeks 0-24 was based on estimate population (EP). The stratum-adjusted between-group difference was tested with the CMH method. The responder proportion analysis for Weeks 28-48 was based on the estimate population (EP). The stratum-adjusted between-group difference was tested with the CMH method. The post-switching data for the two telitacicept groups and the placebo group were handled with the LOCF method, i.e. imputing all the post-switching values with the most recent pre-switching results. •STAR integrates systemic disease activity (ClinESSDAI), symptoms (ESSPRI), and glandular function (Schirmer’s / salivary flow)•Systemic disease activity and patient-reported symptoms are considered as major items (3 points per item) and the rest as minor items (1 point per item)•Patients are classified as STAR responders when they reach ≥ 5 of 9 points 74.8%Telitacicept 160mg 53.2%Telitacicept 80mg 21.3%Placebo Group STAR Responders (%) at Week 24
Page 38
Consistent Reduction in IgG, IgA, IgM, and B Cells 38 -30% -20% -10% 0% 10 % 04812162024283236404448 IGG CHANGE FROM BASELINE (%) (FAS, MEAN±SE ) WEEK 16 0mg80 mgPlaceboIGG -50%-40%-30%-20%-10%0%10 % 04812162024283236404448 IGA CHANGE FROM BASELINE (%) (FAS, MEAN±SE ) WEEK 16 0mg80 mgPlaceboIGA -60%-50%-40%-30%-20%-10%0%10 % 04812162024283236404448 IGM CHANGE FROM BASELINE (%) (FAS, MEAN±SE ) WEEK 16 0mg80 mgPlaceboIGM -80%-60%-40%-20%0%20 %40 % 04812162024283236404448 B CELL CHANGE FROM BASELINE (%) (FAS, MEAN±SE ) WEEK 16 0mg80 mgPlaceboB CELL RemeGen-sponsored trial -24.81% 2.08% -16.33% -45.81% -0.18% -32.48% -58.07% -1.64% -46.46% -63.71% 20.8% -59.62% ###################### ## #####################* ######################## ## #####################ǂ ## (*P<0.05,ϮP<0.01,ǂP<0.001,#P<0.0001)
Page 39
Favorable Safety Profile 39 Consistent with data from clinical trials in SLE, RA, gMG, and IgAN, and post-marketing data TEAE, treatment emergent adverse event; TRAE, treatment related adverse event; TESAE, treatment emergent serious adverse event; TRSAE, treatment related serious adverse event; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; gMG, generalized myasthenia gravis; IgAN, IgA nephropathyRemeGen-sponsored trial Telitacicept 160mg(N=127)Telitacicept 80 mg (N=126)Placebo Group(N=127)TEAE, n(%) 122 (96.1)119 (94.4)112 (88.2)TRAE, n(%) 107 (84.3)106 (84.1)74 (58.3)TESAE, n(%)11 (8.7)14 (11.1)10 (7.9)TRSAE, n(%)2 (1.6)5 (4.0)4 (3.1)Severe TEAE, n(%)3 (2.4)5 (4.0)3 (2.4)Severe TRAE, n(%)0 1 (0.8)1 (0.8)Death, n(%) 0(0)0(0)0(0)Common TEAE (incidence ≥10% in any group) Upper respiratory tract infections, n(%)80 (63.0)85 (67.5)74 (58.3)Urinary tract infection, n(%) 8 (6.3)15 (11.9)7 (5.5)Cough, n(%) 11 (8.7)14 (11.1)8 (6.3)Hepatic function abnormal, n(%) 7 (5.5)16 (12.7)7 (5.5)Injection site reaction, n(%) 53 (41.7)51 (40.5)5 (3.9)Pyrexia, n(%) 4 (3.1)14 (11.1)4 (3.1)
Page 40
pSD Commercial OpportunityDallan Murray, Chief Commercial Officer 40
Page 41
-4.8 -8-7-6-5-4-3-2-10 Telitacicept - Week 24EfgartigimodNipocalimabRozanolixizumabRavulizumabEculizumabZilucoplanInebilizumab Telitacicept: Potential Best-In-Disease Efficacy Globally 41 Statistically significant and clinically meaningful improvement in MG-ADL score PBO-adjusted LSM MG-ADL Change from Baseline Based on historical clinical data; not a head-to-head trialEfgartigimod - ADAPT; Nipocalimab - Vivacity-MG3; Rozanolixizumab – MycarinG; Ravulizumab – CHAMPION-MG; Eculizumab – REGAIN; Zilucoplan – RAISE; Inebilizumab - MINTRemeGen-sponsored trial -7.5 -6.3*-7.5-8 -7 -6 -5 -4 -3 -2 -1 0 04812162024283236404448 LEAST SQUARES MEAN CHANGE FROM BASELINE IN MG-ADL SCORE WEEK 24 0mg Gro upPlacebo MEAN CHANGE IN MG-ADL SCORE† -6.4 -1.6 * Telitacicept arm continue with the same treatment, Placebo arm switched to Telitacicept during OLE period. The efficacy analysis was based on descriptive statistical analysis of the actual data in the full analysis set (FAS), and missing data were not filled.
Page 42
-5 -4 -3 -2 -1 0 Telitacicept Efgartigimod Nipocalimab Ianalumab Dazodalibep Telitacicept: Potential Best-In-Disease Efficacy Globally 42 Statistically significant and clinically meaningful improvement in ESSDAI -4.3 PBO-adjusted LSM ESSDAI Change from Baseline Efgartigimod - RHO; Nipocalimab - Bowman 2022, Lancet; Ianalumab - St. Clair 2024, Nature and Grader-Beck 2025 ACR; Dazodalibep - Xu 2024 RheumatologyESSDAI, EULAR Sjögren’s syndrome disease activity index; mAb, monoclonal antibody n=14n=23n=47n=36n=14 Based on historical clinical data; not a head-to-head trial RemeGen-sponsored trial n=257n=127Phase III DatasetsPhase II Datasets ?-3.8
Page 43
Sjögren’s: One of the Most Common Systemic Autoimmune Diseases Globally 43 ~870,000 diagnosed Sjögren’s patients across key markets1 Favorable Growth Drivers•Rising diagnosis rates from better awareness and testingUnderpenetrated Market•No approved disease-modifying systemic therapies•Patients managed with symptomatic treatments ~290kUS prevalence ~450kEU prevalence ~130kJapan prevalence 1. Vor metanalysis and estimates; excludes Chinese market
Page 44
Prove Efficacy on ESSDAIShow statistically significant ≥3-point reduction in ESSDAIPhase III primary ESSDAI endpoint met with >3-point reduction vs placebo. Must be SafeDeliver a clean, non-cytotoxic B-cell approach; avoid infection or PML risk Favorable safety profile — no PML, minimal infections through BAFF/APRIL modulation to regulate, not eradicate, B cellsLong-Term SafetyProvide multi-year tolerability data supporting chronic useProven long term safety with 10s of thousands of commercially treated patients and ~1,800 patients treated in clinical trialsDeliver Disease ModificationShow modulation of underlying B-cell biology that stabilizes disease course, not just symptomsDual BAFF/APRIL blockade restores B-cell balance and supports long-term disease modification. Telitacicept Checks Every Box — Ideal Profile to Transform Sjögren’s Disease 44 I think just safety data is very important – probably most important We need longer-term safety and real-world data I can't think of anything better than B cell targets and trying to make them safer I think ESSDAI is brilliant “ AlphaSense Expert Calls August - September 2025 At the minimum of two and preferably a three-point improvement in the ESSDAI index Expert InsightsImperativeWhat Telitacicept Has Delivered ““““
Page 45
45 01 TelitaciceptRedefining Success In Autoimmune Disease02 03TelitaciceptThe Most Advanced BAFF/APRIL Inhibitor GloballyValidated mechanism of actionProven pipeline-in-a-productProof of concept in 5+ indications Myasthenia Gravis The Beachhead IndicationSignificant MG-ADL and QMG score reduction at week 48Opportunity to become the first disease modifying therapy in gMG Primary Sjögren’s Disease The First Expansion OpportunityClinically meaningful, statistically clear physician- and patient-reported outcomes Depth and durability across key domainsFavorable, consistent safety profile
Page 46
Linkedin.com/company/vor-bio Vorbio.com Thank You. 46 Investors@vorbio.com